Development and validation of a simple general population lung cancer risk model including AHRR-methylation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Development and validation of a simple general population lung cancer risk model including AHRR-methylation. / Jacobsen, Katja Kemp; Kobylecki, Camilla Jannie; Skov-Jeppesen, Sune Moeller; Bojesen, Stig Egil.

I: Lung Cancer, Bind 181, 107229, 2023.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Jacobsen, KK, Kobylecki, CJ, Skov-Jeppesen, SM & Bojesen, SE 2023, 'Development and validation of a simple general population lung cancer risk model including AHRR-methylation', Lung Cancer, bind 181, 107229. https://doi.org/10.1016/j.lungcan.2023.107229

APA

Jacobsen, K. K., Kobylecki, C. J., Skov-Jeppesen, S. M., & Bojesen, S. E. (2023). Development and validation of a simple general population lung cancer risk model including AHRR-methylation. Lung Cancer, 181, [107229]. https://doi.org/10.1016/j.lungcan.2023.107229

Vancouver

Jacobsen KK, Kobylecki CJ, Skov-Jeppesen SM, Bojesen SE. Development and validation of a simple general population lung cancer risk model including AHRR-methylation. Lung Cancer. 2023;181. 107229. https://doi.org/10.1016/j.lungcan.2023.107229

Author

Jacobsen, Katja Kemp ; Kobylecki, Camilla Jannie ; Skov-Jeppesen, Sune Moeller ; Bojesen, Stig Egil. / Development and validation of a simple general population lung cancer risk model including AHRR-methylation. I: Lung Cancer. 2023 ; Bind 181.

Bibtex

@article{6951b064194d4d40a22f4f7fdf86bf42,
title = "Development and validation of a simple general population lung cancer risk model including AHRR-methylation",
abstract = "Introduction: Screening reduces lung cancer mortality of high-risk populations. Currently proposed screening eligibility criteria only identify half of those individuals, who later develop lung cancer. This study aimed to develop and validate a sensitive and simple model for predicting 10-year lung cancer risk. Methods: Using the 1991–94 examination of The Copenhagen City Heart Study in Denmark, 6,820 former or current smokers from the general population were followed for lung cancer within 10 years after examination. Logistic regression of baseline variables (age, sex, education, chronic obstructive pulmonary disease, family history of lung cancer, smoking status and cumulative smoking, secondhand smoking, occupational exposures to dust and fume, body mass index, lung function, plasma C-reactive protein, and AHRR(cg05575921) methylation) identified the best predictive model. The model was validated among 3,740 former or current smokers from the 2001-03 examination, also followed for 10 years. A simple risk chart was developed with Poisson regression. Results: Age, sex, education, smoking status, cumulative smoking, and AHRR(cg05575921) methylation identified 65 of 88 individuals who developed lung cancer in the validation cohort. The highest risk group, consisting of less educated men aged >65 with current smoking status and cumulative smoking >20 pack-years, had absolute 10-year risks varying from 4% to 16% by AHRR(cg05575921) methylation. Conclusion: A simple risk chart including age, sex, education, smoking status, cumulative smoking, and AHRR(cg05575921) methylation, identifies individuals with 10-year lung cancer risk from below 1% to 16%. Including AHRR(cg05575921) methylation in the eligibility criteria for screening identifies smokers who would benefit the most from screening.",
keywords = "AHRR (cg05575921) methylation, Aryl hydrocarbon receptor, DNA methylation, Epigenetic biomarker, Longitudinal study, Lung cancer, Lung cancer screening, Predictive biomarkers, Survival, Tobacco smoking",
author = "Jacobsen, {Katja Kemp} and Kobylecki, {Camilla Jannie} and Skov-Jeppesen, {Sune Moeller} and Bojesen, {Stig Egil}",
note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",
year = "2023",
doi = "10.1016/j.lungcan.2023.107229",
language = "English",
volume = "181",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Development and validation of a simple general population lung cancer risk model including AHRR-methylation

AU - Jacobsen, Katja Kemp

AU - Kobylecki, Camilla Jannie

AU - Skov-Jeppesen, Sune Moeller

AU - Bojesen, Stig Egil

N1 - Publisher Copyright: © 2023 The Author(s)

PY - 2023

Y1 - 2023

N2 - Introduction: Screening reduces lung cancer mortality of high-risk populations. Currently proposed screening eligibility criteria only identify half of those individuals, who later develop lung cancer. This study aimed to develop and validate a sensitive and simple model for predicting 10-year lung cancer risk. Methods: Using the 1991–94 examination of The Copenhagen City Heart Study in Denmark, 6,820 former or current smokers from the general population were followed for lung cancer within 10 years after examination. Logistic regression of baseline variables (age, sex, education, chronic obstructive pulmonary disease, family history of lung cancer, smoking status and cumulative smoking, secondhand smoking, occupational exposures to dust and fume, body mass index, lung function, plasma C-reactive protein, and AHRR(cg05575921) methylation) identified the best predictive model. The model was validated among 3,740 former or current smokers from the 2001-03 examination, also followed for 10 years. A simple risk chart was developed with Poisson regression. Results: Age, sex, education, smoking status, cumulative smoking, and AHRR(cg05575921) methylation identified 65 of 88 individuals who developed lung cancer in the validation cohort. The highest risk group, consisting of less educated men aged >65 with current smoking status and cumulative smoking >20 pack-years, had absolute 10-year risks varying from 4% to 16% by AHRR(cg05575921) methylation. Conclusion: A simple risk chart including age, sex, education, smoking status, cumulative smoking, and AHRR(cg05575921) methylation, identifies individuals with 10-year lung cancer risk from below 1% to 16%. Including AHRR(cg05575921) methylation in the eligibility criteria for screening identifies smokers who would benefit the most from screening.

AB - Introduction: Screening reduces lung cancer mortality of high-risk populations. Currently proposed screening eligibility criteria only identify half of those individuals, who later develop lung cancer. This study aimed to develop and validate a sensitive and simple model for predicting 10-year lung cancer risk. Methods: Using the 1991–94 examination of The Copenhagen City Heart Study in Denmark, 6,820 former or current smokers from the general population were followed for lung cancer within 10 years after examination. Logistic regression of baseline variables (age, sex, education, chronic obstructive pulmonary disease, family history of lung cancer, smoking status and cumulative smoking, secondhand smoking, occupational exposures to dust and fume, body mass index, lung function, plasma C-reactive protein, and AHRR(cg05575921) methylation) identified the best predictive model. The model was validated among 3,740 former or current smokers from the 2001-03 examination, also followed for 10 years. A simple risk chart was developed with Poisson regression. Results: Age, sex, education, smoking status, cumulative smoking, and AHRR(cg05575921) methylation identified 65 of 88 individuals who developed lung cancer in the validation cohort. The highest risk group, consisting of less educated men aged >65 with current smoking status and cumulative smoking >20 pack-years, had absolute 10-year risks varying from 4% to 16% by AHRR(cg05575921) methylation. Conclusion: A simple risk chart including age, sex, education, smoking status, cumulative smoking, and AHRR(cg05575921) methylation, identifies individuals with 10-year lung cancer risk from below 1% to 16%. Including AHRR(cg05575921) methylation in the eligibility criteria for screening identifies smokers who would benefit the most from screening.

KW - AHRR (cg05575921) methylation

KW - Aryl hydrocarbon receptor

KW - DNA methylation

KW - Epigenetic biomarker

KW - Longitudinal study

KW - Lung cancer

KW - Lung cancer screening

KW - Predictive biomarkers

KW - Survival

KW - Tobacco smoking

U2 - 10.1016/j.lungcan.2023.107229

DO - 10.1016/j.lungcan.2023.107229

M3 - Journal article

C2 - 37150141

AN - SCOPUS:85158047464

VL - 181

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

M1 - 107229

ER -

ID: 366339616